Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Hwail Pharm Co., Ltd. (061250:KRX), powered by AI.
Hwail Pharm Co., Ltd. is currently trading at ₩8,210. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Hwail Pharm Co., Ltd. on Alpha Lenz.
Hwail Pharm Co., Ltd.'s P/E ratio is -281.4.
“Hwail Pharm Co., Ltd. trades at a P/E of -281.4 (undervalued) with modest ROE of -0.1%.”
Ask for details →Hwail Pharm Co., Ltd. is a distinguished company in the pharmaceutical sector that specializes in the research, development, and production of various pharmaceutical products. With a robust focus on innovation, it fosters advancements in medical treatments and health solutions. The company's product portfolio typically includes a range of medicinal drugs, catering to ailments across different therapeutic areas. Hwail Pharm Co., Ltd. plays a critical role in the healthcare industry by contributing to the enhancement of public health through its pharmaceutical offerings. Known for adhering to high-quality standards, it ensures that its products comply with stringent regulatory requirements, thus maintaining trust among healthcare professionals and patients alike. Its impact is felt across hospitals, pharmacies, and clinics, where its products are used to improve patient care and outcomes. As part of its market presence, Hwail Pharm Co., Ltd. is committed to the continuous development of its product lines and exploring new treatment avenues, thereby holding a significant place in the pharmaceutical market.
“Hwail Pharm Co., Ltd. trades at a P/E of -281.4 (undervalued) with modest ROE of -0.1%.”
Ask for details →Hwail Pharm Co., Ltd. (ticker: 061250) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). Market cap is $65.6B.
The current price is ₩8,210 with a P/E ratio of -281.41x and P/B of 0.32x.
ROE is -0.11% and operating margin is -2.25%. Annual revenue is $100.8B.